title: American college of cardiology 57th scientific sessions, 2008.
abstract: The peak-interest clinical trials at the American College of Cardiology (ACC) Scientific Sessions, which took place from March 29 to April 2, 2008, are generally ushered into the high-profile Late-Breaking Clinical Trials sessions. This year, the ENHANCE trial (Effect of Combination Ezetimibe and High-Dose Simvastatin vs. Simvastatin Alone on the Atherosclerotic Process in Patients with Heterozygous Familial Hypercholesterolemia) was precluded from the "Late-Breakers" because a peek at the unexpectedly disappointing data had already been afforded in January.Amid pre-meeting publicity about allegedly inappropriate data delays (and a Congressional hearing delving into them), the ACC created a special plenary session "Showcase" presentation of the data with a review panel for comment. The ENHANCE findings intensified interest in both non-lipid-lowering benefits of statins and non-statins for lipid lowering. This 57th ACC conference hosted a record 29,000 attendees in Chicago, Illinois.
authors: Reuben B
authors: RB
authors: David